StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Investment analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Price Performance

Cytosorbents stock opened at $0.88 on Friday. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.97. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The firm’s fifty day moving average is $0.96 and its 200 day moving average is $1.01. The company has a market cap of $48.11 million, a price-to-earnings ratio of -2.44 and a beta of 0.57.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently made changes to their positions in the business. Atomi Financial Group Inc. bought a new stake in Cytosorbents during the 3rd quarter valued at about $51,000. CM Management LLC boosted its holdings in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the period. Geode Capital Management LLC grew its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC increased its holdings in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the period. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.